Valuation: Celldex Therapeutics, Inc.

Market Cap 2.68B 2.35B 2.17B 2.02B 3.8B 252B 3.87B 25.98B 10.06B 124B 10.05B 9.83B 433B P/E 2026 *
-7.86x
P/E 2027 * -7.8x
Enterprise Value 2.09B 1.84B 1.69B 1.58B 2.97B 197B 3.02B 20.31B 7.87B 97.29B 7.85B 7.68B 338B EV / Sales 2026 *
794x
EV / Sales 2027 * 181x
Free-Float
99.73%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 67 29/07/2014
Chief Executive Officer 64 31/08/2008
Director of Finance/CFO 55 31/03/2009
Director TitleAgeSince
Director/Board Member 64 30/11/2008
Chairman 80 04/06/2025
Director/Board Member 93 29/02/2008
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 2.65B
+1.67%+8.90%-5.75%+1.40% 45.45B
+4.95%+9.31%+363.86%+598.16% 36.09B
-0.64%+1.92%+3.08%+53.58% 30.81B
+0.44%+11.12%+17.47%-12.91% 30.98B
+0.23%-0.86%+12.75%+21.10% 24.62B
+9.90%+13.32% - - 14.78B
+1.40%+12.99%+67.11%+132.76% 14.65B
+1.88%+8.59%+13.76%+20.68% 13.3B
+2.38%+5.69%+95.85%+97.63% 12.65B
Average +2.47%+6.21%+71.02%+114.05% 24.81B
Weighted average by Cap. +2.13%+6.42%+77.68%+128.88%

Financials

2026 *2027 *
Net sales 2.63M 2.31M 2.13M 1.99M 3.74M 249M 3.81M 25.58M 9.91M 123M 9.89M 9.68M 426M 11.96M 10.51M 9.68M 9.05M 16.98M 1.13B 17.29M 116M 44.99M 556M 44.92M 43.94M 1.93B
Net income -330M -290M -267M -250M -468M -31.14B -477M -3.2B -1.24B -15.35B -1.24B -1.21B -53.35B -370M -325M -300M -280M -526M -34.96B -535M -3.6B -1.39B -17.23B -1.39B -1.36B -59.89B
Net Debt -584M -513M -473M -442M -829M -55.12B -844M -5.67B -2.2B -27.17B -2.19B -2.15B -94.42B -507M -446M -411M -384M -720M -47.88B -733M -4.93B -1.91B -23.6B -1.91B -1.86B -82.02B
Logo Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
34.09USD
Average target price
57.53USD
Spread / Average Target
+68.77%

Quarterly revenue - Rate of surprise